SrasV1, Main, Exploration, bibRecord, 004E02

Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus

Identifieur interne : 004E02 ( Main/Exploration ); précédent : 004E01; suivant : 004E03

Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus

Auteurs : Masayuki Saijo [Japon] ; Shigeru Morikawa [Japon] ; Shuetsu Fukushi [Japon] ; Tetsuya Mizutani [Japon] ; Hideki Hasegawa [Japon] ; Noriyo Nagata [Japon] ; Naoko Iwata [Japon] ; Ichiro Kurane [Japon]

Source :

Antiviral research [ 0166-3542 ] ; 2005.

RBID : Pascal:05-0266881

Descripteurs français

KwdFr :
- Animaux, Antiviraux (), Antiviraux (pharmacologie), Cellules Vero, Ribavirine (), Ribavirine (pharmacologie), Ribonucléosides (), Ribonucléosides (pharmacologie), Réplication virale (), Tests de sensibilité microbienne, Virus du SRAS (), Virus du SRAS (enzymologie), Virus du SRAS (génétique), Virus du SRAS (physiologie).
MESH :
- enzymologie : Virus du SRAS.
- génétique : Virus du SRAS.
- pharmacologie : Antiviraux, Ribavirine, Ribonucléosides.
- physiologie : Virus du SRAS.
Pascal (Inist)
- Animaux, Antiviraux, Cellules Vero, Mizoribine, Ribavirine, Ribonucléosides, Réplication, Réplication virale, Syndrome respiratoire aigu sévère, Tests de sensibilité microbienne, Virus du SRAS, Virus syndrome respiratoire aigu sévère, Relation structure activité, Antifongique, Immunodépresseur, Antiviral.

English descriptors

KwdEn :
- Animals, Antifungal agent, Antiviral, Antiviral Agents (chemistry), Antiviral Agents (pharmacology), Chlorocebus aethiops, Immunosuppressive agent, Microbial Sensitivity Tests, Mizoribine, Replication, Ribavirin, Ribavirin (chemistry), Ribavirin (pharmacology), Ribonucleosides (chemistry), Ribonucleosides (pharmacology), SARS Virus (drug effects), SARS Virus (enzymology), SARS Virus (genetics), SARS Virus (physiology), Severe acute respiratory syndrome, Severe acute respiratory syndrome virus, Structure activity relation, Vero Cells, Virus Replication (drug effects).
MESH :
- chemical , chemistry : Antiviral Agents, Ribavirin, Ribonucleosides.
- chemical , pharmacology : Antiviral Agents, Ribavirin, Ribonucleosides.
- drug effects : SARS Virus, Virus Replication.
- enzymology : SARS Virus.
- genetics : SARS Virus.
- physiology : SARS Virus.
- Animals, Chlorocebus aethiops, Microbial Sensitivity Tests, Vero Cells.

Abstract

The activity of inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors, mizoribine and ribavirin, against severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) was determined by plaque reduction and yield reduction assays. Mizoribine and ribavirin selectively inhibited replication of SARS-CoV. The 50% inhibitory concentration (IC₅₀) of mizoribine for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, as determined by plaque reduction was 3.5 μg/ml and 16 μg/ml, respectively, and the IC₅₀ of ribavirin for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849 was 20 μg/ml and 80 μg/ml, while the 50% cytotoxic concentration of mizoribine and ribavirin for Vero E6 cells exceeded 200 μg/ml. In a yield reduction assay, mizoribine (10 μg/ml) and ribavirin (40 μg/ml) inhibited the replication of SARS-CoV and reduced the infectious SARS-CoV titers to one-tenth or less. Mizoribine inhibited replication of SARS-CoV more strongly than ribavirin. However, neither drug could completely inhibit replication of SARS-CoV even at concentrations up to 100 μg/ml.

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus</title>
<author><name sortKey="Saijo, Masayuki" sort="Saijo, Masayuki" uniqKey="Saijo M" first="Masayuki" last="Saijo">Masayuki Saijo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases</s1>
<s2>Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morikawa, Shigeru" sort="Morikawa, Shigeru" uniqKey="Morikawa S" first="Shigeru" last="Morikawa">Shigeru Morikawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases</s1>
<s2>Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases</s1>
<s2>Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mizutani, Tetsuya" sort="Mizutani, Tetsuya" uniqKey="Mizutani T" first="Tetsuya" last="Mizutani">Tetsuya Mizutani</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases</s1>
<s2>Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hasegawa, Hideki" sort="Hasegawa, Hideki" uniqKey="Hasegawa H" first="Hideki" last="Hasegawa">Hideki Hasegawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Laboratory of Infectious Disease Pathology, Department of Pathology, National Institute of Infectious Diseases</s1>
<s2>Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nagata, Noriyo" sort="Nagata, Noriyo" uniqKey="Nagata N" first="Noriyo" last="Nagata">Noriyo Nagata</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Laboratory of Infectious Disease Pathology, Department of Pathology, National Institute of Infectious Diseases</s1>
<s2>Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Iwata, Naoko" sort="Iwata, Naoko" uniqKey="Iwata N" first="Naoko" last="Iwata">Naoko Iwata</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Laboratory of Infectious Disease Pathology, Department of Pathology, National Institute of Infectious Diseases</s1>
<s2>Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kurane, Ichiro" sort="Kurane, Ichiro" uniqKey="Kurane I" first="Ichiro" last="Kurane">Ichiro Kurane</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases</s1>
<s2>Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0266881</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0266881 INIST</idno>
<idno type="RBID">Pascal:05-0266881</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000662</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000328</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000621</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000621</idno>
<idno type="wicri:doubleKey">0166-3542:2005:Saijo M:inhibitory:effect:of</idno>
<idno type="wicri:Area/Main/Merge">005141</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15911031</idno>
<idno type="wicri:Area/PubMed/Corpus">002721</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002721</idno>
<idno type="wicri:Area/PubMed/Curation">002721</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002721</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002647</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002647</idno>
<idno type="wicri:Area/Ncbi/Merge">000F68</idno>
<idno type="wicri:Area/Ncbi/Curation">000F68</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000F68</idno>
<idno type="wicri:doubleKey">0166-3542:2005:Saijo M:inhibitory:effect:of</idno>
<idno type="wicri:Area/Main/Merge">004A62</idno>
<idno type="wicri:Area/Main/Curation">004E02</idno>
<idno type="wicri:Area/Main/Exploration">004E02</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus</title>
<author><name sortKey="Saijo, Masayuki" sort="Saijo, Masayuki" uniqKey="Saijo M" first="Masayuki" last="Saijo">Masayuki Saijo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases</s1>
<s2>Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morikawa, Shigeru" sort="Morikawa, Shigeru" uniqKey="Morikawa S" first="Shigeru" last="Morikawa">Shigeru Morikawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases</s1>
<s2>Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases</s1>
<s2>Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mizutani, Tetsuya" sort="Mizutani, Tetsuya" uniqKey="Mizutani T" first="Tetsuya" last="Mizutani">Tetsuya Mizutani</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases</s1>
<s2>Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hasegawa, Hideki" sort="Hasegawa, Hideki" uniqKey="Hasegawa H" first="Hideki" last="Hasegawa">Hideki Hasegawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Laboratory of Infectious Disease Pathology, Department of Pathology, National Institute of Infectious Diseases</s1>
<s2>Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nagata, Noriyo" sort="Nagata, Noriyo" uniqKey="Nagata N" first="Noriyo" last="Nagata">Noriyo Nagata</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Laboratory of Infectious Disease Pathology, Department of Pathology, National Institute of Infectious Diseases</s1>
<s2>Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Iwata, Naoko" sort="Iwata, Naoko" uniqKey="Iwata N" first="Naoko" last="Iwata">Naoko Iwata</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Laboratory of Infectious Disease Pathology, Department of Pathology, National Institute of Infectious Diseases</s1>
<s2>Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kurane, Ichiro" sort="Kurane, Ichiro" uniqKey="Kurane I" first="Ichiro" last="Kurane">Ichiro Kurane</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Special Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases</s1>
<s2>Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Japon</country>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antifungal agent</term>
<term>Antiviral</term>
<term>Antiviral Agents (chemistry)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Chlorocebus aethiops</term>
<term>Immunosuppressive agent</term>
<term>Microbial Sensitivity Tests</term>
<term>Mizoribine</term>
<term>Replication</term>
<term>Ribavirin</term>
<term>Ribavirin (chemistry)</term>
<term>Ribavirin (pharmacology)</term>
<term>Ribonucleosides (chemistry)</term>
<term>Ribonucleosides (pharmacology)</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (enzymology)</term>
<term>SARS Virus (genetics)</term>
<term>SARS Virus (physiology)</term>
<term>Severe acute respiratory syndrome</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Structure activity relation</term>
<term>Vero Cells</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antiviraux ()</term>
<term>Antiviraux (pharmacologie)</term>
<term>Cellules Vero</term>
<term>Ribavirine ()</term>
<term>Ribavirine (pharmacologie)</term>
<term>Ribonucléosides ()</term>
<term>Ribonucléosides (pharmacologie)</term>
<term>Réplication virale ()</term>
<term>Tests de sensibilité microbienne</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (enzymologie)</term>
<term>Virus du SRAS (génétique)</term>
<term>Virus du SRAS (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiviral Agents</term>
<term>Ribavirin</term>
<term>Ribonucleosides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Ribavirin</term>
<term>Ribonucleosides</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Ribavirine</term>
<term>Ribonucléosides</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Microbial Sensitivity Tests</term>
<term>Vero Cells</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Animaux</term>
<term>Antiviraux</term>
<term>Cellules Vero</term>
<term>Mizoribine</term>
<term>Ribavirine</term>
<term>Ribonucléosides</term>
<term>Réplication</term>
<term>Réplication virale</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Tests de sensibilité microbienne</term>
<term>Virus du SRAS</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Relation structure activité</term>
<term>Antifongique</term>
<term>Immunodépresseur</term>
<term>Antiviral</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The activity of inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors, mizoribine and ribavirin, against severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) was determined by plaque reduction and yield reduction assays. Mizoribine and ribavirin selectively inhibited replication of SARS-CoV. The 50% inhibitory concentration (IC<sub>50</sub>
) of mizoribine for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, as determined by plaque reduction was 3.5 μg/ml and 16 μg/ml, respectively, and the IC<sub>50</sub>
 of ribavirin for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849 was 20 μg/ml and 80 μg/ml, while the 50% cytotoxic concentration of mizoribine and ribavirin for Vero E6 cells exceeded 200 μg/ml. In a yield reduction assay, mizoribine (10 μg/ml) and ribavirin (40 μg/ml) inhibited the replication of SARS-CoV and reduced the infectious SARS-CoV titers to one-tenth or less. Mizoribine inhibited replication of SARS-CoV more strongly than ribavirin. However, neither drug could completely inhibit replication of SARS-CoV even at concentrations up to 100 μg/ml.</div>
</front>
</TEI>
<affiliations><list><country><li>Japon</li>
</country>
<region><li>Région de Kantō</li>
</region>
<settlement><li>Tokyo</li>
</settlement>
</list>
<tree><country name="Japon"><region name="Région de Kantō"><name sortKey="Saijo, Masayuki" sort="Saijo, Masayuki" uniqKey="Saijo M" first="Masayuki" last="Saijo">Masayuki Saijo</name>
</region>
<name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name>
<name sortKey="Hasegawa, Hideki" sort="Hasegawa, Hideki" uniqKey="Hasegawa H" first="Hideki" last="Hasegawa">Hideki Hasegawa</name>
<name sortKey="Iwata, Naoko" sort="Iwata, Naoko" uniqKey="Iwata N" first="Naoko" last="Iwata">Naoko Iwata</name>
<name sortKey="Kurane, Ichiro" sort="Kurane, Ichiro" uniqKey="Kurane I" first="Ichiro" last="Kurane">Ichiro Kurane</name>
<name sortKey="Mizutani, Tetsuya" sort="Mizutani, Tetsuya" uniqKey="Mizutani T" first="Tetsuya" last="Mizutani">Tetsuya Mizutani</name>
<name sortKey="Morikawa, Shigeru" sort="Morikawa, Shigeru" uniqKey="Morikawa S" first="Shigeru" last="Morikawa">Shigeru Morikawa</name>
<name sortKey="Nagata, Noriyo" sort="Nagata, Noriyo" uniqKey="Nagata N" first="Noriyo" last="Nagata">Noriyo Nagata</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004E02 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004E02 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:05-0266881
   |texte=   Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus

Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.